Cargando…

Dasatinib and Doxorubicin Treatment of Sarcoma Initiating Cells: A Possible New Treatment Strategy

Background. One of the major challenges affecting sarcoma treatment outcome, particularly that of metastatic disease, is resistance to chemotherapy. Cancer-initiating cells are considered a major contributor to this resistance. Methods. An immortalised nontransformed human stromal (mesenchymal) stem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aggerholm-Pedersen, Ninna, Demuth, Christina, Safwat, Akmal, Meldgaard, Peter, Kassem, Moustapha, Sandahl Sorensen, Boe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693025/ https://www.ncbi.nlm.nih.gov/pubmed/26788073 http://dx.doi.org/10.1155/2016/9601493

Ejemplares similares

Pazopanib in the Treatment of Bone Sarcomas: Clinical Experience()
por: Aggerholm-Pedersen, Ninna, et al.
Publicado: (2019)

A Validated Prognostic Biomarker Score for Adult Patients with Nonmetastatic Soft Tissue Sarcomas of the Trunk and Extremities
por: Maretty-Kongstad, Katja, et al.
Publicado: (2017)

The Prognostic Value of Serum Biomarkers in Localized Bone Sarcoma()
por: Aggerholm-Pedersen, Ninna, et al.
Publicado: (2016)

Comorbidity in Adult Bone Sarcoma Patients: A Population-Based Cohort Study
por: Aggerholm-Pedersen, Ninna, et al.
Publicado: (2014)

Population-based Aarhus Sarcoma Registry: validity, completeness of registration, and incidence of bone and soft tissue sarcomas in western Denmark
por: Maretty-Nielsen, Katja, et al.
Publicado: (2013)

The Importance of Reference Gene Analysis of Formalin-Fixed, Paraffin-Embedded Samples from Sarcoma Patients — An Often Underestimated Problem()()
por: Aggerholm-Pedersen, Ninna, et al.
Publicado: (2014)

Relative mortality in soft tissue sarcoma patients: a Danish population-based cohort study
por: Maretty-Nielsen, Katja, et al.
Publicado: (2014)

Rhabdomyosarcoma in Adults: A Retrospective Analysis of Case Records Diagnosed between 1979 and 2018 in Western Denmark
por: Mäkinen, Vivi-Nelli, et al.
Publicado: (2021)

A method for treatment monitoring using circulating tumour DNA in cancer patients without targetable mutations
por: Demuth, Christina, et al.
Publicado: (2018)

The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment
por: Demuth, Christina, et al.
Publicado: (2018)

Serum Natrium Determines Outcome of Treatment of Advanced GIST with Imatinib: A Retrospective Study of 80 Patients from a Single Institution
por: Aggerholm-Pedersen, Ninna, et al.
Publicado: (2011)

Targeted Treatment of Soft-Tissue Sarcoma
por: Riskjell, Anne Iren, et al.
Publicado: (2023)

A prognostic profile of hypoxia-induced genes for localised high-grade soft tissue sarcoma
por: Aggerholm-Pedersen, Ninna, et al.
Publicado: (2016)

Prognostic factors for local recurrence and mortality in adult soft tissue sarcoma of the extremities and trunk wall: A cohort study of 922 consecutive patients
por: Maretty-Nielsen, Katja, et al.
Publicado: (2014)

Inflammatory Cytokines and ctDNA Are Biomarkers for Progression in Advanced-Stage Melanoma Patients Receiving Checkpoint Inhibitors
por: Pedersen, Jesper Geert, et al.
Publicado: (2020)

Increased Soluble PD-1 Predicts Response to Nivolumab plus Ipilimumab in Melanoma
por: Pedersen, Jesper Geert, et al.
Publicado: (2022)

Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients
por: Winther-Larsen, Anne, et al.
Publicado: (2017)

Tumoral PD-L1 does not impact time to treatment discontinuation in EGFR mutated non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor—a Danish cohort study
por: Dissing, Julie Gabe, et al.
Publicado: (2022)

cGAS-STING pathway expression as a prognostic tool in NSCLC
por: Raaby Gammelgaard, Kristine, et al.
Publicado: (2021)

Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC
por: Ulhoi, Maiken Parm, et al.
Publicado: (2021)

Increased PD-L1 expression in erlotinib-resistant NSCLC cells with MET gene amplification is reversed upon MET-TKI treatment
por: Demuth, Christina, et al.
Publicado: (2017)

Role of high‑sensitivity C‑reactive protein in patients with sarcoma
por: Aggerholm-Pedersen, Ninna, et al.
Publicado: (2023)

Analysis of circulating tumor DNA during checkpoint inhibition in metastatic melanoma using a tumor-agnostic panel
por: Kisistók, Judit, et al.
Publicado: (2023)

Chondrosarcoma: the impact of comorbidity – 30 years of experience from a population-based database including 199 consecutive chondrosarcoma patients
por: Aggerholm-Pedersen, Ninna, et al.
Publicado: (2019)

Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients()
por: Winther-Larsen, Anne, et al.
Publicado: (2016)

Cell‐free chromatin immunoprecipitation can determine tumor gene expression in lung cancer patients
por: Trier Maansson, Christoffer, et al.
Publicado: (2023)

Macrophage Biomarkers sCD163 and sSIRPα in Serum Predict Mortality in Sarcoma Patients
por: Aggerholm-Pedersen, Ninna, et al.
Publicado: (2023)

Genomic Profiling of Circulating Tumor DNA Predicts Outcome and Demonstrates Tumor Evolution in ALK-Positive Non-Small Cell Lung Cancer Patients
por: Madsen, Anne Tranberg, et al.
Publicado: (2020)

EGFR transcription in non‐small‐cell lung cancer tumours can be revealed in ctDNA by cell‐free chromatin immunoprecipitation (cfChIP)
por: Månsson, Christoffer Trier, et al.
Publicado: (2021)

DNAfusion: an R/Bioconductor package for increased sensitivity of detecting gene fusions in liquid biopsies
por: Maansson, Christoffer Trier, et al.
Publicado: (2023)

Inclusion of Metabolic Tumor Volume in Prognostic Models of Bone and Soft Tissue Sarcoma Increases the Prognostic Value
por: Pedersen, Mette Abildgaard, et al.
Publicado: (2023)

Neurofilament Light Chain as A Biomarker for Brain Metastases
por: Winther-Larsen, Anne, et al.
Publicado: (2020)

Low-Grade Fibromyxoid Sarcoma: Incidence, Treatment Strategy of Metastases, and Clinical Significance of the FUS Gene
por: Maretty-Nielsen, Katja, et al.
Publicado: (2013)

A Phase I/II Clinical Trial of Belinostat (PXD101) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas
por: Vitfell-Rasmussen, Joanna, et al.
Publicado: (2016)

Inflammation scores as prognostic biomarkers in small cell lung cancer: a systematic review and meta-analysis
por: Winther-Larsen, Anne, et al.
Publicado: (2021)

Hyponatremia as a prognostic factor in non-small cell lung cancer: a systematic review and meta-analysis
por: Sandfeld-Paulsen, Birgitte, et al.
Publicado: (2021)

Inflammation-scores as prognostic markers of overall survival in lung cancer: a register-based study of 6,210 Danish lung cancer patients
por: Winther-Larsen, Anne, et al.
Publicado: (2022)

Pretreatment Albumin-to-Alkaline Phosphatase Ratio Is a Prognostic Marker in Lung Cancer Patients: A Registry-Based Study of 7077 Lung Cancer Patients
por: Sandfeld-Paulsen, Birgitte, et al.
Publicado: (2021)

Measuring KRAS Mutations in Circulating Tumor DNA by Droplet Digital PCR and Next-Generation Sequencing
por: Demuth, Christina, et al.
Publicado: (2018)

Blood tumor mutational burden and dynamic changes in circulating tumor DNA predict response to pembrolizumab treatment in advanced non-small cell lung cancer
por: Stensgaard, Simone, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6r2o0clceqf12ku3of8lpgkftc